HOXA13 serves as a biomarker to predict neoadjuvant therapy efficacy in advanced colorectal cancer patients: HOXA13 predicts neoadjuvant therapy efficacy of CRC

Neoadjuvant therapy (NAT) for advanced colorectal cancer (ACRC) is a kind of well-evidenced therapy, yet a portion of ACRC patients have poor therapeutic response. To date, no suitable biomarker used for assessing NAT efficacy has been reported. Here, we collect 72 colonoscopy biopsy tissue specimen...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Shuanghui, Zhang, Rui, Yang, Zhengquan, Wang, Yajiao, Guo, Xingxiu, Zhao, Youjuan, Lin, Huangjue, Xiang, Youqun, Ding, Chunming, Dong, Zhixiong, Xu, Chang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157630/
https://www.ncbi.nlm.nih.gov/pubmed/36514224
http://dx.doi.org/10.3724/abbs.2022182

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10157630/
https://www.ncbi.nlm.nih.gov/pubmed/36514224
http://dx.doi.org/10.3724/abbs.2022182

Ejemplares similares